Day: November 30, 2021

Novakova-Jiresova, A; Kopeckova, K; Boublikova, L; Chloupkov, R; Melichar, B; Petruzelka, L; Finek, J; Fiala, O; Grell, P; Batko, S; Linke, Z; Kiss, I; Prausov, J; Buchler, T in [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic; [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic; [Kopeckova, Katerina; Batko, Stanislav; Linke, Zdenek; Prausov, Jana] Charles Univ Prague, Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Chloupkov, Renata] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic; [Melichar, Bohuslav] Palacky Univ Med, Dept Oncol, Olomouc, Czech Republic; [Melichar, Bohuslav] Teaching Hosp, Olomouc, Czech Republic; [Petruzelka, Lubos] Charles Univ Prague, Gen Fac Hosp, Dept Oncol, Prague, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Med Sch, Dept Oncol & Radiotherapy, Plzen, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Univ Hosp Pilsen, Plzen, Czech Republic; [Fiala, Ondrej] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic; [Grell, Peter; Kiss, Igor] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic published Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients in 2020, Cited 30. Recommanded Product: 83-10-3. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3.

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

Recommanded Product: 83-10-3. Welcome to talk about 83-10-3, If you have any questions, you can contact Novakova-Jiresova, A; Kopeckova, K; Boublikova, L; Chloupkov, R; Melichar, B; Petruzelka, L; Finek, J; Fiala, O; Grell, P; Batko, S; Linke, Z; Kiss, I; Prausov, J; Buchler, T or send Email.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Product Details of 86-92-0. Recently I am researching about ENANTIOSELECTIVE ADDITION; TERTIARY ALCOHOLS; PYRAZOLONE DERIVATIVES; ORGANOZINC REAGENTS; ALKYLZINC REAGENTS; ALPHA-KETOESTERS; KETONES; DIETHYLZINC; HYDROXYLATION; DIMETHYLZINC, Saw an article supported by the Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [YJ201853, YJ201805]; National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [21907072]. Published in WILEY-V C H VERLAG GMBH in WEINHEIM ,Authors: Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE. The CAS is 86-92-0. Through research, I have a further understanding and discovery of 3-Methyl-1-p-tolyl-5-pyrazolone

The catalytic enantioselective diorganozinc additions to cyclic diketones including pyrazolin-4,5-diones and isatins have been developed. In the presence of morpholine-containing chiral amino alcohol ligand, the corresponding chiral cyclic tertiary alcohols were produced in good to excellent yields (up to 97 %) and enantioselectivities (up to 95 % ee). The notable feature of this protocol includes its mild reaction conditions, Lewis acid additives free and broad functional group tolerance.

Product Details of 86-92-0. Welcome to talk about 86-92-0, If you have any questions, you can contact Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE or send Email.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 2021 CHEM COMMUN published article about PHOTOPHYSICAL PROPERTIES; ACTIVATION; FUNCTIONALIZATION; MECHANISM in [Changmai, Sumi; Sultana, Sabera; Gogoi, Sanjib] North East Inst Sci & Technol, CSIR, Chem Sci & Technol Div, Appl Organ Chem, Jorhat 785006, Assam, India; [Changmai, Sumi; Sultana, Sabera; Gogoi, Sanjib] AcSIR, Ghaziabad 201002, India; [Sarma, Bipul] Tezpur Univ, Dept Chem Sci, Tezpur 784028, Assam, India in 2021, Cited 30. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0. Category: pyrazoles-derivatives

The Pd(ii)-catalyzed activation of Csp(2)-H bond and double alkyne annulation which proceeds via allylic isomerization is reported for the first time. This reaction of antipyrines with alkynes provides an efficient synthetic route for the biologically important spiro-cyclopentadiene pyrazolones. In the presence of Lawesson’s reagent, this Pd(ii)-catalyzed annulation reaction affords another spiro-cyclopentadiene pyrazolone which displays very good fluorescence properties.

Category: pyrazoles-derivatives. Welcome to talk about 86-92-0, If you have any questions, you can contact Changmai, S; Sultana, S; Sarma, B; Gogoi, S or send Email.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Name: 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. In 2019 JMIR MHEALTH UHEALTH published article about HEART-RATE-VARIABILITY; WORK-LIFE BALANCE; BURNOUT; SURGEONS; STRESS; SATISFACTION; TONE in [Peters, Gregory Andrew; Wong, Matthew L.; Joseph, Joshua W.; Sanchez, Leon D.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, 1 Deaconess Rd, Boston, MA 02215 USA; [Peters, Gregory Andrew; Wong, Matthew L.; Joseph, Joshua W.; Sanchez, Leon D.] Harvard Med Sch, Boston, MA 02115 USA in 2019, Cited 40. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3.

Background: The high prevalence of physician burnout, particularly in emergency medicine, has garnered national attention in recent years. Objective means of measuring stress while at work can facilitate research into stress reduction interventions, and wearable photoplethysmography (PPG) technology has been proposed as a potential solution. However, the use of low-burden wearable biosensors to study training and clinical practice among emergency physicians (EP) remains untested. Objective: This pilot study aimed to (1) determine the feasibility of recording on-shift photoplethysmographic data from EP, (2) assess the quality of these data, and (3) calculate standard pulse rate variability (PRV) metrics from the acquired dataset and examine patterns in these variables over the course of an academic year. Methods: A total of 21 EP wore PPG biosensors on their wrists during clinical work in the emergency department during a 9-hour shift. Recordings were collected during the first quarter of the academic year, then again during the fourth quarter of the same year for comparison. The overall rate of usable data collection per time was computed. Standard pulse rate (PR) and PRV metrics from these two time points were calculated and entered into Student t tests. Results: More than 400 hours of data were entered into these analyses. Interpretable data were captured during 8.54% of the total recording time overall. In the fourth quarter of the academic year compared with the first quarter, there was no significant difference in median PR (75.8 vs 76.8; P=.57), mean R-R interval (0.81 vs 0.80; P=.32), SD of R-R interval (0.11 vs 0.11; P=.93), root mean square of successive difference of R-R interval (0.81 vs 0.80; P=.96), low-frequency power (3.5×103 vs 3.4×103; P=.79), high-frequency power (8.5×103 vs 8.3×103; P=.91), or low-frequency to high-frequency ratio (0.42 vs 0.41; P=.43), respectively. Power estimates for each of these tests exceeded .90. A secondary analysis of the resident-only subgroup similarly showed no significant differences over time, despite power estimates greater than .80. Conclusions: Although the use of PPG biosensors to record real-time physiological data from EP while providing clinical care seems operationally feasible, this study fails to support the notion that such an approach can efficiently provide reliable estimates of metrics of interest. No significant differences in PR or PRV metrics were found at the end of the year compared with the beginning. Although these methods may offer useful applications to other domains, it may currently have limited utility in the contexts of physician training and wellness.

Welcome to talk about 83-10-3, If you have any questions, you can contact Peters, GA; Wong, ML; Joseph, JW; Sanchez, LD or send Email.. Name: 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

An article Household disaster preparedness in the Islamic Republic of Iran: 2015 estimation WOS:000527367000004 published article about MANAGEMENT; EDUCATION; PROGRAM; RISK in [Ardalan, Ali; Yusefi, Homa] Univ Tehran Med Sci, Sch Publ Hlth, Dept Disaster & Emergency Hlth, Tehran, Iran; [Ardalan, Ali] Harvard Univ, Harvard Humanitarian Initiat, Cambridge, MA 02138 USA; [Yusefi, Homa; Rouhi, Narges; Banar, Ahad] Minist Hlth & Med Educ, Dept Publ Hlth, Disaster Risk Management Off, Tehran, Iran; [Sohrabizadeh, Sanaz] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Dept Hlth Disasters & Emergencies, Tehran, Iran in 2020, Cited 25. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3. Formula: C12H12N2O3

Background: The Islamic Republic of Iran is at high risk of natural disasters. Households are the basic unit of society and they need to be prepared for disasters. Aims: This study assessed disaster preparedness among Iranian households in 2015. Methods: Using multistage cluster sampling, 2968 households in the catchment area of 53 public health departments in all 30 provinces of the Islamic Republic of Iran were surveyed on the disaster preparedness measures they had taken in the past year. The data collection questionnaire included 15 disaster preparedness measures. The mean preparedness score was calculated and its association with residence (urban versus rural), house ownership (owner versus renter) and education level of the head of the household (illiterate, elementary school, middle school, high school, university) was evaluated. Results: The mean score for household disaster preparedness was 9.3 out of 100 (95% confidence interval: 8.3-10.3). Multivariate analysis showed higher preparedness among rural than urban households (P = 0.02). Higher education level was positively associated with a higher preparedness score (P < 0.001), as was house ownership (P < 0.001). Conclusion: The level of household disaster preparedness in the Islamic Republic of Iran in 2015 was low. In line with the first priority for action of the Sendai Framework for Disaster Risk Reduction, the current study provides an overall picture of household disaster preparedness in the Islamic Republic of Iran. This estimation can be used as a baseline value for policy-making, planning, and evaluation of public awareness of disasters in the country. Formula: C12H12N2O3. Welcome to talk about 83-10-3, If you have any questions, you can contact Ardalan, A; Yusefi, H; Rouhi, N; Banar, A; Sohrabizadeh, S or send Email.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Quality Control of 3,5-Dimethyl-1H-pyrazole. I found the field of Polymer Science very interesting. Saw the article Synthesis of blocked waterborne polyurethane with 3,5-dimethylpyrazole for industrial application in digital inkjet printing published in 2019.0, Reprint Addresses Wang, XM (corresponding author), Sun Yat Sen Univ, Minist Educ, Sch Chem, Key Lab Polymer Composite & Funct Mat, Guangzhou 510275, Guangdong, Peoples R China.. The CAS is 67-51-6. Through research, I have a further understanding and discovery of 3,5-Dimethyl-1H-pyrazole.

In this article, a series of blocked waterborne polyurethanes (BWPUs) were synthesized by isophorone diisocyanate, polyols, dimethylol butanoic acid (DMBA), and 3,5-dimethylpyrazole. BWPUs were applied to digital inkjet printing of textiles. The successful synthesis and deblocking of BWPU were confirmed by Fourier transform infrared spectroscopy and differential scanning calorimetry. The colorfastness was improved by deblocking the terminal NCO groups at 140 degrees C, which could react with fiber. This article presented a characterization method of filtering rate to evaluate the fluency of inkjet printing. Besides, the digital microscope was used to investigate the pigment transferred to the white test cloth. In the end, we chose poly(ethylene glycol adipate) 2000 as the polyol, 1,4-butanediol as the chain extender, 1.6 as the NCO/OH molar ratio, and 4% as the mass fraction of DMBA. (c) 2019 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2019, 136, 47765.

Quality Control of 3,5-Dimethyl-1H-pyrazole. Welcome to talk about 67-51-6, If you have any questions, you can contact Yin, Q; Wang, XM; Chen, JH; Wu, XF; Zheng, JY or send Email.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Authors Dhanju, S; Caravana, AC; Thomson, RJ in AMER CHEMICAL SOC published article about CARBON BOND FORMATION; AMMONIUM-NITRATE in [Dhanju, Sandeep; Caravana, Aidan C.; Thomson, Regan J.] Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA in 2020.0, Cited 21.0. Application In Synthesis of 3,5-Dimethyl-1H-pyrazole. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6

The synthesis of alpha-pyrazole and alpha-triazole derivatives of ketones by the ceric ammonium nitrate-mediated oxidative coupling of enolsilanes with heteroarenes is reported. The reaction proceeds under mild reaction conditions to provide a diversity of products, including sterically hindered fully substituted derivatives.

Application In Synthesis of 3,5-Dimethyl-1H-pyrazole. Welcome to talk about 67-51-6, If you have any questions, you can contact Dhanju, S; Caravana, AC; Thomson, RJ or send Email.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

An article Use of pyrazoles as ligands greatly enhances the catalytic activity of titanium iso-propoxide for the ring-opening polymerization of l-lactide: a cooperation effect WOS:000588975500011 published article about COMPLEXES BEARING; STRUCTURAL-CHARACTERIZATION; INITIATORS; POLYMERS; ROP; NANOPARTICLES; IMPROVEMENT; ALKOXIDES in [Wang, Tzu-Fang; Kosuru, Someswara Rao; Yu, Shu-Chun; Chang, Yung-Chi; Lai, Hsin-Yu; Chang, Yu-Lun; Ding, Shangwu; Chen, Hsuan-Ying] Kaohsiung Med Univ, Drug Dev & Value Creat Res Ctr, Dept Med & Appl Chem, Kaohsiung 80708, Taiwan; [Wu, Kuo-Hui] Univ Tokyo, Grad Sch Sci, Dept Chem, Tokyo 1130033, Japan; [Wu, Kuo-Hui] Tamkang Univ, Dept Chem, Tamsui 251, Taiwan; [Ding, Shangwu; Chen, Hsuan-Ying] Natl Sun Yat Sen Univ, Dept Chem, Kaohsiung 80424, Taiwan; [Chen, Hsuan-Ying] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 80708, Taiwan in 2020.0, Cited 69.0. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6. Recommanded Product: 3,5-Dimethyl-1H-pyrazole

Using TiOⁱPr4 with a pyrazole ligand for one-pot LA polymerization improved catalytic activity compared with using TiOⁱPr4 only. At 60 degrees C, TiOⁱPr4 with ^furPz exhibited a higher catalytic activity (approximately 3-fold) than TiOⁱPr4. At room temperature, TiOⁱPr4 with ^BuPz exhibited a higher catalytic activity (approximately 17-fold) than TiOⁱPr4. High molecular mass PLA (MnGPC = 51 100, and D = 1.10) could be produced by using TiOⁱPr4 with ^furPz in melt polymerization ([TiOⁱPr4] : [^furPz] = 1000 : 1 : 1 at 100 degrees C, 240 min). The crystal structure of ^MePz2Ti2OⁱPr7 revealed the cooperative activation between two Ti atoms during LA polymerization.

Recommanded Product: 3,5-Dimethyl-1H-pyrazole. Bye, fridends, I hope you can learn more about C5H8N2, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

In 2021.0 J ORG CHEM published article about REGIOSELECTIVE IODINATION; NITROSYLSULFURIC ACID; AROMATIC-COMPOUNDS; EFFICIENT METHOD; NITROGEN-OXIDE; C-13 NMR; MILD; CONVENIENT; BROMINATION; 3,5-DIARYLISOXAZOLES in [Bondarenko, Oksana B.; Karetnikov, Georgy L.; Komarov, Arseniy, I; Pavlov, Aleksandr, I; Nikolaeva, Svetlana N.] Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119991, Russia in 2021.0, Cited 58.0. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6. Product Details of 67-51-6

A new convenient and versatile halogenating system (R(4)NHal/NOHSO4), giving straightforward and general access to halogenated 3,5-diaryl- and alkylarylisoxazoles, pyrazoles and electron-rich benzenes from the corresponding scaffolds, is suggested. The method provides excellent regioselectivity, scalability to the gram scale, and a broad scope for both aromatics and halogens. A three-step, one-pot reaction protocol was developed, and a series of 3,5-diaryl-4-haloisoxazoles has been efficiently synthesized from 1,2-diarylcyclopropanes under suggested nitrosating-halogenating conditions.

Product Details of 67-51-6. Welcome to talk about 67-51-6, If you have any questions, you can contact Bondarenko, OB; Karetnikov, GL; Komarov, AI; Pavlov, AI; Nikolaeva, SN or send Email.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

SDS of cas: 83-10-3. In 2020 CANCER MANAG RES published article about CLINICAL-PRACTICE; SURVIVAL; MULTICENTER; ANTITUMOR; SAFETY; SITE; SEX in [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic; [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic; [Kopeckova, Katerina; Batko, Stanislav; Linke, Zdenek; Prausov, Jana] Charles Univ Prague, Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Chloupkov, Renata] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic; [Melichar, Bohuslav] Palacky Univ Med, Dept Oncol, Olomouc, Czech Republic; [Melichar, Bohuslav] Teaching Hosp, Olomouc, Czech Republic; [Petruzelka, Lubos] Charles Univ Prague, Gen Fac Hosp, Dept Oncol, Prague, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Med Sch, Dept Oncol & Radiotherapy, Plzen, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Univ Hosp Pilsen, Plzen, Czech Republic; [Fiala, Ondrej] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic; [Grell, Peter; Kiss, Igor] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic in 2020, Cited 30. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3.

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

SDS of cas: 83-10-3. Bye, fridends, I hope you can learn more about C12H12N2O3, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics